Scarica l'app Stockscreener
3.39
1.80%
0.06
Dopo l'orario di chiusura:
3.38
-0.01
-0.29%
Precedente Chiudi:
$3.33
Aprire:
$3.35
Volume 24 ore:
159.92K
Relative Volume:
0.39
Capitalizzazione di mercato:
$130.79M
Reddito:
-
Utile/perdita netta:
$-42.05M
Rapporto P/E:
-1.2021
EPS:
-2.82
Flusso di cassa netto:
$-35.26M
1 W Prestazione:
+7.62%
1M Prestazione:
+17.71%
6M Prestazione:
-28.03%
1 anno Prestazione:
+41.84%
Intervallo 1D:
$3.25
$3.405
Intervallo di 1 settimana:
$3.07
$3.45
Portata 52W:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Nome
Protara Therapeutics Inc
Settore
Industria
Telefono
646-844-0337
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK, NY
Confronta TARA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.39 | 128.48M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-16 | Iniziato | Scotiabank | Sector Outperform |
| 2025-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Ripresa | Guggenheim | Buy |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-17 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-07-29 | Iniziato | Guggenheim | Buy |
Mostra tutto
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Protara Therapeutics Inc. Stock Analysis and ForecastHigh-octane investment gains - Autocar Professional
What drives Protara Therapeutics Inc. stock priceUnmatched market performance - jammulinksnews.com
Is Protara Therapeutics Inc. a good long term investmentRapid growth trajectories - jammulinksnews.com
Protara Therapeutics (NASDAQ:TARA) Shares Up 11% – Still a Buy? - Defense World
What analysts say about Protara Therapeutics Inc. stockTremendous portfolio expansion - jammulinksnews.com
Best Banking Stocks AI Stock ForecastsRapidly expanding wealth - PrintWeekIndia
What analysts say about Arvinas Inc. stockFree Stock Movement Tracking - jammulinksnews.com
Is Armada Hoffler Properties Inc. a good long term investmentExplosive earning power - jammulinksnews.com
DGICB Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com
Will Protara Therapeutics Inc. stock split in the near futureDaily Top Gainers - Newser
Why Protara Therapeutics Inc. stock attracts strong analyst attentionFree Capital Allocation Plans - beatles.ru
What makes Protara Therapeutics Inc. stock price move sharplyMinimized Risk Trading Plan - Newser
How Protara Therapeutics Inc. stock performs during market volatilityStable Stocks With High Yield - Newser
Protara Therapeutics Awards 44,250 Equity Grants Worth $2.80 Per Share to Strategic New Hires - Stock Titan
TARA SEC FilingsProtara Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Protara Therapeutics, Inc.(NasdaqGM: TARA) added to Russell 3000E Index - MarketScreener
Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Buy” by Brokerages - Defense World
Protara Therapeutics (TARA) Drops 3.69% to 2024 Low - AInvest
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Why EchoStar Stock Is Soaring Higher Today - The Globe and Mail
Two Sigma Investments LP Cuts Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025 (NASDAQ:TARA) - Seeking Alpha
SoundHound AI (SOUN): This High-Potential Growth Stock Could Be Your Smartest Bet under $10 - The Globe and Mail
Where Will Uber Stock Be in 5 Years? - The Globe and Mail
Company News for Jun 13, 2025 - The Globe and Mail
Protara Therapeutics: Clinical Milestones and Robust Liquidity Fuel Near-Term Upside - AInvest
Protara Therapeutics Holds Annual Stockholders Meeting - TipRanks
These 3 ‘Bro Billionaire’ Stocks Are Wildly Outperforming in Trump’s Market - The Globe and Mail
Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail
Cantor Fitzgerald Forecasts TARA FY2026 Earnings - Defense World
Squarepoint Ops LLC Makes New $110,000 Investment in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Steven Hudson buying at ECN Capital (ECN) - The Globe and Mail
Protara Therapeutics, Inc. (NASDAQ:TARA) Position Increased by Bank of America Corp DE - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of “Buy” by Analysts - Defense World
Protara Therapeutics Inc Azioni (TARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):